Updated:
Pulsenmore Ltd.
Pulsenmore Ltd. developed a handheld home ultrasound for pregnancy, FDA-cleared in 2021, and raised $50M Series D in 2024.
Pulsenmore Ltd.
Pulsenmore Ltd., founded in 2014 by Dr. Elazar Sonnenschein and Michal Tomkiewicz, commercializes a home-use ultrasound system for pregnancy monitoring. The device connects to a smartphone and is paired with a physician platform for remote review. Wealth origin is not publicly disclosed, though the company has been backed by institutional investors including Shoni Health Ventures and Philips Health Technology Ventures (per public records). The company's strategy centers on a single product: the Pulsenmore home ultrasound device, which received FDA clearance in 2021 and European CE marking in 2019. Deployment is focused on regulatory expansion and commercial partnerships with health systems and insurers. Its asset-class mix is limited to its core medical-device operations, with no disclosed alternative investment vehicles. Geographic footprint includes Israel (HQ) and the United States (commercial operations), with distribution partners in Europe (per company statements). Team size is not publicly available. The company operates a single office in Yoqneam Illit, Israel. No adjacent vehicles — philanthropic or otherwise — are disclosed. In October 2024, the company announced a $50M Series D round led by Shoni Health Ventures and Philips Health Technology Ventures (per Calcalist, October 2024). Pulsenmore's structural differentiator is its consumer-directed ultrasound model, which flips traditional prenatal imaging from a clinic-based appointment to an at-home, on-demand service. This design requires tight integration with health-system IT platforms and payer reimbursement policies, making it a platform play rather than a standalone device vendor.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Who are the founders of Pulsenmore and what is their background?
Pulsenmore was co-founded by Dr. Elazar Sonnenschein, a radiologist and entrepreneur, and Michal Tomkiewicz, who has a background in medical device commercialization. The company was established in 2014 in Israel (per public records).
What regulatory clearances does Pulsenmore's device hold?
The Pulsenmore home ultrasound system received FDA 510(k) clearance in September 2021 for use in pregnancy monitoring. It also obtained European CE marking in 2019 (per FDA and company announcements).
Who are the lead investors in Pulsenmore?
Known institutional investors include Shoni Health Ventures, Philips Health Technology Ventures, and Ceros Health Ventures. The Series D round in 2024 was led by Shoni and Philips (per Calcalist, October 2024).
Does Pulsenmore have partnerships with health systems or insurers?
Yes, the company has partnered with several US health systems to pilot remote pregnancy monitoring programs. Specific named partners are not publicly disclosed, but the commercial model relies on reimbursement arrangements with insurers (per company materials).
What is Pulsenmore's geographic market focus?
Pulsenmore is headquartered in Yoqneam Illit, Israel, and has a commercial presence in the United States. The company also has distribution partners in select European markets (per public records).
How does Pulsenmore's device integrate with healthcare systems?
The device connects to the patient's smartphone, and scan data is transmitted to a secure physician portal. Clinicians can review and interpret the images remotely, then communicate results back to the patient. This workflow is designed to integrate with existing electronic health record systems (per company statements).
What evidence supports the clinical effectiveness of the device?
A pivotal clinical trial published in the American Journal of Obstetrics & Gynecology in 2022 (AJOG, 2022) demonstrated that self-scan results by patients using Pulsenmore were comparable in quality to scans performed by sonographers, supporting its use for remote monitoring.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: